Is There a Place for PD-1-PD-L Blockade in Acute Myeloid Leukemia?

• Hauptverfasser: Laura Jimbu (VerfasserIn), Oana Mesaros (VerfasserIn), Cristian Popescu (VerfasserIn), Alexandra Neaga (VerfasserIn), Iulia Berceanu (VerfasserIn), Delia Dima (VerfasserIn), Mihaela Gaman (VerfasserIn), Mihnea Zdrenghea (VerfasserIn)
• Format: Buch
• Veröffentlicht: MDPI AG, 2021-03-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Checkpoint inhibitors were a major breakthrough in the field of oncology. In September 2014, based on the KEYNOTE-001 study, the Food and Drug Administration (FDA) approved pembrolizumab, a programmed cell death protein 1 (PD-1) inhibitor, for advanced or unresectable melanoma. Up until now, seven P...